

Clinical Policy Advisory Group (CPAG)

CLINICAL & GOVERNANCE POLICIES UPDATED PROCEDURES OF LIMITED CLINICAL VALUE POLICIES

Research evidence shows that some interventions are not clinically effective or only effective when they are performed in specific circumstances. The purpose of the Procedures of Limited Clinical Value (PLCV) policy is to clarify the commissioning intentions of the Integrated Care Board (ICB). The ICB will only fund treatment for clinically effective interventions that are then delivered to the appropriate cohort of patients.

Clinical Policy	Background
Gamete Storage Policy (Planned stakeholder engagement for full routine review to take place)	<p>In February 2019, a draft Gamete Storage Policy was agreed by all East Midlands CCGs including Derby & Derbyshire CCG. A Public consultation process was undertaken by Leicestershire CCG, on behalf of all the East Midland CCGs, with the intention of the East Midlands Affiliated Commissioning Committee (EMACC) producing a final policy. Due to Covid-19, this work was put on hold and although it was EMACC's intention to produce a final version for CCGs/ICBs to ratify prior to the 1st July 2022, EMACC has subsequently disbanded and this work has not been completed. In the meantime, the Derbyshire policy is now due for review. As a final East Midlands Gamete Storage Policy has not been produced and ratified, CPAG agreed to consult fully with local stakeholders on the DDICB policy.</p> <p>In line with National Guidance, CPAG has agreed to consult on including the following groups of patients who are undergoing NHS funded medical or surgical treatment with a risk of causing permanent infertility:</p> <ul style="list-style-type: none"> • Patients with autoimmune conditions requiring chemotherapy • Rare mitochondrial disorders • Conditions requiring special endocrinology services <p>Although the Gamete Storage Policy does not guarantee eligibility for fertility treatment, it is in line with the DDICB existing policies in regard to living children.</p>

MISCELLANEOUS INFORMATION

Statement	Summary
IVF Policy – East Midlands Collaborative Review	<p>A discussion took place at the September 2022 CPAG meeting in regard to NHS DDICB involvement in a collaborative review of the IVF Policy, with other East Midlands ICB's.</p> <p>The Terms of Reference have been requested and the East Midlands Group is currently considering next steps. As a result no further action will be taken at present by CPAG.</p> <p>The Derbyshire IVF policy is current and continues to be updated on a 3 yearly basis. CPAG recently reviewed and approved the DDICB IVF Policy in June 2022.</p>
Individual Funding Requests (IFR) Screening Cases	<p>CPAG reviewed the IFR Screening cases for September 2022 and are assured that no areas for service development have been identified.</p>
NICE Early Value Assessment	<p>NICE launched an Early Value Assessment (EVA) programme for its MedTech outputs. The objective is to offer rapid assessment of digital products devices and diagnostics for clinical effectiveness and value for money which will enable services and patients to be able to benefit sooner. Through Early Value Assessment, commissioners will be assured they are choosing products that offer real potential value while further evidence is being developed.</p> <p>DDICB Policy on NICE Outputs remains current, and no change will be required as the result of the launch of EVA. i.e. all other technologies not covered by the MedTech Funding Mandate are not commissioned and require the submission and subsequent approval of a business case as per the Interventional Procedure Policy.</p> <p>This pilot approach to rapid assessments, may not be restricted to MedTech evaluations, and could potentially cover multi-NICE outputs i.e. Diagnostic and Medical Technology Guidance. There are currently a number of EVA's in development which relate to Diagnostic technology.</p> <p>The first two pilots are expected to be digital apps for depression and anxiety in children, and others are expected to follow:</p> <ul style="list-style-type: none"> • adult mental health, • early cancer diagnosis, • cardiovascular disease, • other areas that support elective recovery following the pandemic. <p>NICE issued draft guidance in August 2022 (publication date 17th October 2022) recommending KardiaMobile 6L for measuring cardiac QT interval in people having antipsychotic medication which is part of the NICE DTG programme.</p>

NICE INTERVENTIONAL PROCEDURES GUIDANCE, DIAGNOSTIC PROCEDURES, MEDICAL TECHNOLOGIES GUIDANCE AND MEDTECH INNOVATION BRIEFINGS (IPGS, DTG, MTGS, MIBS)

The DDICB does not commission and will not fund any procedure or technology assessed by NICE under their IPG, MTG, DTG and MIB programmes unless:

- the provider has submitted a robust, evidenced based business case to the commissioner and this has been subsequently approved AND
- the NICE IPG states 'use with standard arrangements for clinical governance, consent and audit'
- OR the NICE MTG states 'the case for adoption within the NHS as described is supported by the evidence'
- OR the NICE DTG makes a recommendation as an option for use
- OR the NICE MIB has evaluated the innovation.

The following NICE programme outputs were noted by the group for the month of September 2022:

IPG/MTG/DTG/MIB	Description	Outcome
IPG737	Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia	Special arrangements – DDICB do not commission
IPG738	Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause	Further research – DDICB do not commission
IPG739	Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain	Special arrangements – DDICB do not commission
MTG38	Neuropad for detecting preclinical diabetic peripheral neuropathy	Not recommended – DDICB do not commission
MIB306	iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia	Not commissioned without the provider submitting a robust, evidenced based business case to the commissioner and subsequent approval

Our ICB continues to monitor and implement NICE outputs e.g. IPGs with our main providers.